The management of locally advanced prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue , 2002, Pages S8-S11

  Valicenti, R K ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Hormone therapy; Locally advanced prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; TABLET FORMULATION; WORKSHOP;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0036393253     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500620     Document Type: Article

References (11)

1. Iversen P et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582.
2. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52-74.
3. Nakashima J et al. Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer 1997; 80: 237-241.
4. Zelefsky MJ et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241-249.
5. Blasko JC et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002; 12: 81-94.
6. BollaM et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997; 337: 295-300.
7. Lawton CA et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
8. Pilepich MV et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
9. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999; 35 (Suppl 1): 23-25.
10. See WA et al. Bicalutamide ('Casodex') 150mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002; 168: 429-435.
11. Tyrrell C et al. Bicalutamide ('Casodex') 150mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2001; 51(3 Suppl 1): 15-16 (Abstract 22).